Phenylephrine Hydrochloride Injection Recalled for Manufacturing Practice Deviations
Accord Healthcare is recalling 5,090 vials of Phenylephrine Hydrochloride Injection due to manufacturing deviations found during an FDA inspection. Affected batches include R2101570, R2101574, and R2101576, distributed in the United States, Puerto Rico, and Canada.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This recall received a High score because it involves a risk-of-harm product (injectable medication with manufacturing process deviations) where no injury has been reported. The FDA Class II classification confirms potential for serious adverse health consequences, meeting the rubric criterion for high-risk products.
Plain-English summary
Accord Healthcare, Inc. is recalling 5,090 vials of Phenylephrine Hydrochloride Injection, USP (10 mg/mL, 5 mL vials) due to Current Good Manufacturing Practice (CGMP) deviations identified during an FDA inspection. The FDA classified this as a Class II recall.
The recalled product was distributed throughout the United States, including Puerto Rico and Canada. The affected vials include batches R2101570, R2101574, and R2101576 with an expiration date of November 30, 2023. The product is identified by NDC 16729-465-31 (individual vials) and NDC 16729-465-03 (cartons).
Healthcare providers and hospitals should immediately discontinue use of vials from the affected batches. Affected product should be returned to the pharmacy or distributor. Patients currently receiving this medication should consult with their healthcare provider to confirm they received product from an unaffected batch.
The recalled product
- Product
- Phenylephrine Hydrochloride Injection, USP, 50 mg/5mL (10 mg/mL), Rx Only, 5 mL Vial, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA; Vial NDC 16729-465-31, UPC 3 16729 46531 1; Carton
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Injection
- Hazard
- Affected units
- 5,090
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Batches: R2101570
- R2101574
- R2101576
- Exp. Date 11/30/2023
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 67 recalled by Accord Healthcare, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same manufacturer · Accord Healthcare, Inc.
See all →- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19